3979 related articles for article (PubMed ID: 18668363)
41. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction.
Iwao K; Miyoshi Y; Egawa C; Ikeda N; Tsukamoto F; Noguchi S
Cancer; 2000 Oct; 89(8):1732-8. PubMed ID: 11042568
[TBL] [Abstract][Full Text] [Related]
42. Expression of human telomerase reverse transcriptase gene and protein, and of estrogen and progesterone receptors, in breast tumors: preliminary data from neo-adjuvant chemotherapy.
Kammori M; Izumiyama N; Hashimoto M; Nakamura K; Okano T; Kurabayashi R; Naoki H; Honma N; Ogawa T; Kaminishi M; Takubo K
Int J Oncol; 2005 Nov; 27(5):1257-63. PubMed ID: 16211220
[TBL] [Abstract][Full Text] [Related]
43. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer.
Thorpe SM; Rose C; Rasmussen BB; Mouridsen HT; Bayer T; Keiding N
Cancer Res; 1987 Nov; 47(22):6126-33. PubMed ID: 3664512
[TBL] [Abstract][Full Text] [Related]
44. Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer: progesterone receptor B hypermethylation in breast cancer.
Mc Cormack O; Chung WY; Fitzpatrick P; Cooke F; Flynn B; Harrison M; Fox E; Gallagher E; McGoldrick A; Dervan PA; McCann A; Kerin MJ
Breast Cancer Res Treat; 2008 Sep; 111(1):45-53. PubMed ID: 17896177
[TBL] [Abstract][Full Text] [Related]
45. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
46. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
[TBL] [Abstract][Full Text] [Related]
47. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
48. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
Linardou H; Kalogeras KT; Kronenwett R; Kouvatseas G; Wirtz RM; Zagouri F; Gogas H; Christodoulou C; Koutras AK; Samantas E; Pectasides D; Bafaloukos D; Fountzilas G
Breast Cancer Res; 2012 Nov; 14(6):R145. PubMed ID: 23146280
[TBL] [Abstract][Full Text] [Related]
49. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
50. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
51. Rho GDP dissociation inhibitor alpha expression correlates with the outcome of CMF treatment in invasive ductal breast cancer.
Ronneburg H; Span PN; Kantelhardt E; Dittmer A; Schunke D; Holzhausen HJ; Sweep FC; Dittmer J
Int J Oncol; 2010 Feb; 36(2):379-86. PubMed ID: 20043072
[TBL] [Abstract][Full Text] [Related]
52. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
Torrisi R; Balduzzi A; Ghisini R; Rocca A; Bottiglieri L; Giovanardi F; Veronesi P; Luini A; Orlando L; Viale G; Goldhirsch A; Colleoni M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):667-72. PubMed ID: 18064460
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers.
Rosa FE; Caldeira JR; Felipes J; Bertonha FB; Quevedo FC; Domingues MA; Moraes Neto FA; Rogatto SR
Hum Pathol; 2008 May; 39(5):720-30. PubMed ID: 18234277
[TBL] [Abstract][Full Text] [Related]
54. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
[TBL] [Abstract][Full Text] [Related]
55. Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer.
Mita K; Zhang Z; Ando Y; Toyama T; Hamaguchi M; Kobayashi S; Hayashi S; Fujii Y; Iwase H; Yamashita H
Jpn J Clin Oncol; 2007 Aug; 37(8):575-82. PubMed ID: 17675285
[TBL] [Abstract][Full Text] [Related]
56. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
57. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.
Castellano I; Allia E; Accortanzo V; Vandone AM; Chiusa L; Arisio R; Durando A; Donadio M; Bussolati G; Coates AS; Viale G; Sapino A
Breast Cancer Res Treat; 2010 Dec; 124(3):607-17. PubMed ID: 20127405
[TBL] [Abstract][Full Text] [Related]
58. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
Zhou B; Yang DQ; Xie F
Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
[TBL] [Abstract][Full Text] [Related]
59. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
Stendahl M; Rydén L; Nordenskjöld B; Jönsson PE; Landberg G; Jirström K
Clin Cancer Res; 2006 Aug; 12(15):4614-8. PubMed ID: 16899609
[TBL] [Abstract][Full Text] [Related]
60. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
